滤泡性淋巴瘤预后和分层治疗策略  

Prognosis and stratification strategy for treatment follicular lymphoma

作　　者：叶琇锦[1] 钱文斌[1] 

机构地区：[1]浙江大学附属第一医院血液科,杭州310003

出　　处：《中国实用内科杂志》2015年第2期99-101,共3页Chinese Journal of Practical Internal Medicine

基　　金：国家自然科学基金(81370645);浙江省卫生厅课题(2010KYA006);浙江省重点科技创新团队(2011R50015)

摘　　要：滤泡性淋巴瘤(FL)是一种较为常见的惰性淋巴瘤,具有异质性。多数患者表现为无症状淋巴结肿大,因此诊断时患者往往处于进展期,其特点是初始治疗后很容易复发、复发后的挽救治疗获得的缓解期短,所以FL的治疗还有争议。近年来,利妥昔单抗的应用显著改善了患者的预后。目前采用的治疗策略是根据患者的病理分级、临床分期和危险因素进行分层治疗。文章就FL的预后因素及分层治疗进展作一综述。Follicular lymphomas（FL）are heterogeneous group of indolent nodal lymphomas. Despite much progress over the last two decades,including the advent of the anti-CD20 antibody, a cure for FL has remained elusive. Treatment options for patients with FL are still controversial. This review provides a general state-of-the-art overview in the management of patients with FL and a brief description regarding the current prognostic tools available for treatment decisions.

关 键 词：滤泡性淋巴瘤 病理分期 

分 类 号：R551.2[医药卫生—血液循环系统疾病]